2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Vaso-Occlusive Crises: new trials by email Literature Review of Vaso-Occlusive Crises trials Research Report on Vaso-Occlusive Crises
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets - Sickle Cell Disease | Phase 3 | Active not recruiting | Forma Therapeutics, Inc. | 450 | 2021-01-29 | 2026-04-06 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Crizanlizumab (SEG101), Placebo - Sickle Cell Disease (SCD) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 253 | 2019-07-26 | 2026-10-14 |
Anemia, Sickle Cell (2) · Hematologic Diseases (2) · Sickle Cell Trait (2) · Anemia (1) · Anemia, Hemolytic (1) · Genetic Diseases, Inborn (1) · Hemoglobinopathies (1) · Hemolysis (1)
Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Hemic and Lymphatic Diseases (2) · Anemia (1) · Anemia, Hemolytic (1) · Genetic Diseases, Inborn (1) · Hemoglobinopathies (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
crizanlizumab (1)
Forma Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1)
Canada (2) · France (2) · Germany (2) · Ghana (2) · Greece (2) · India (2) · Italy (2) · Lebanon (2) · Oman (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2) · Belgium (1) · Brazil (1)
PMID 37254256, PMID 35019238, PMID 40088922
2017 (1)